Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.
By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank.
The company will now offer free genetic testing to patients at risk for acute hepatic porphyrias, a class of diseases for which it is developing a treatment.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
Through this Alnylam-funded program, Invitae will perform free testing for US patients suspected to have hereditary ATTR amyloidosis or a family history of it.
The court found that the university had failed to demonstrate that one of its researchers had collaborated with the IP's inventors and therefore is not entitled to co-inventorship.
The firm also said it aims to soon begin human studies for its hepatic porphyria treatment ALN-AS1 and to select a development candidate for its program in primary hyperoxaluria type 1.
The drug is designed to silence complement component C5, whose loss is associated with an attenuated immune response against certain infections.
The proceeds will be used to advance its drug candidates and for general corporate purposes.
The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.
Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.
The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.
US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.
In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.